Collins Stewart: United Therapeutics Reiterates FY12/FY13 Revenue Guidance, Despite 4Q11 Miss

In a research report published earlier today by Collins Stewart, United Therapeutics UTHR reported 4Q11 total revenues of $195.2M this morning, below Street consensus of $204.8M. According to Collins Stewart, “4Q11 GAAP EPS was $0.77, also below consensus of $0.87 and CSe of $0.84, with lower revenue and higher stock-based compensation partially offset by lower tax expense. The company reiterated its FY12 revenue guidance of $831M to $919M (vs. consensus of $880.3M and CSe of $896.2M) and its FY13 revenue guidance of $950M to $1.1B (vs. consensus of $982.2M and CSe of $999.8M).” Collins Stewart maintains its Buy rating and $56 PT on United Therapeutics, which closed yesterday at $49.26.